These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26221017)

  • 1. Surveillance for antimicrobial resistance in Australian isolates of Clostridium difficile, 2013-14.
    Knight DR; Giglio S; Huntington PG; Korman TM; Kotsanas D; Moore CV; Paterson DL; Prendergast L; Huber CA; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV
    J Antimicrob Chemother; 2015 Nov; 70(11):2992-9. PubMed ID: 26221017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J; Vernon J; Pilling S; Morris K; Nicholson S; Shearman S; Longshaw C; Wilcox MH;
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of MCB3681 against Clostridium difficile strains.
    Rashid MU; Dalhoff A; Weintraub A; Nord CE
    Anaerobe; 2014 Aug; 28():216-9. PubMed ID: 25016084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium difficile clade 5 in Australia: antimicrobial susceptibility profiling of PCR ribotypes of human and animal origin.
    Knight DR; Riley TV
    J Antimicrob Chemother; 2016 Aug; 71(8):2213-7. PubMed ID: 27130808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility patterns of Clostridium difficile strains belonging to different polymerase chain reaction ribotypes isolated in Poland in 2012.
    Lachowicz D; Pituch H; Obuch-Woszczatyński P
    Anaerobe; 2015 Feb; 31():37-41. PubMed ID: 25242196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes.
    Freeman J; Vernon J; Morris K; Nicholson S; Todhunter S; Longshaw C; Wilcox MH;
    Clin Microbiol Infect; 2015 Mar; 21(3):248.e9-248.e16. PubMed ID: 25701178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Clostridium difficile Isolates from Human Subjects and the Environment.
    Tian TT; Zhao JH; Yang J; Qiang CX; Li ZR; Chen J; Xu KY; Ciu QQ; Li RX
    PLoS One; 2016; 11(3):e0151964. PubMed ID: 27011211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015.
    Karlowsky JA; Adam HJ; Kosowan T; Baxter MR; Nichol KA; Laing NM; Golding G; Zhanel GG
    Diagn Microbiol Infect Dis; 2018 Jun; 91(2):105-111. PubMed ID: 29456070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea.
    Kim J; Kang JO; Pai H; Choi TY
    Int J Antimicrob Agents; 2012 Jul; 40(1):24-9. PubMed ID: 22578765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes.
    Androga GO; Knight DR; Lim SC; Foster NF; Riley TV
    Anaerobe; 2018 Dec; 54():55-60. PubMed ID: 30053486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH; Kim H; Kim JL; Kim D; Jeong SH; Shin JH; Kim YA; Shin JH; Shin KS; Uh Y
    Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in antimicrobial susceptibility and PCR ribotypes of Clostridioides difficile in a hospital over 5 years: Correlation analysis with antimicrobial consumption.
    Seo MR; Kim B; Kim J; Pai H
    Int J Antimicrob Agents; 2019 Aug; 54(2):154-158. PubMed ID: 31173866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia.
    Lim SC; Androga GO; Knight DR; Moono P; Foster NF; Riley TV
    Int J Antimicrob Agents; 2018 Sep; 52(3):411-415. PubMed ID: 29802886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of Clostridium difficile ribotype 027 in hospitals of Silesia, Poland.
    Aptekorz M; Szczegielniak A; Wiechuła B; Harmanus C; Kuijper E; Martirosian G
    Anaerobe; 2017 Jun; 45():106-113. PubMed ID: 28216085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea.
    Kim H; Jeong SH; Roh KH; Hong SG; Kim JW; Shin MG; Kim MN; Shin HB; Uh Y; Lee H; Lee K
    Korean J Lab Med; 2010 Oct; 30(5):491-7. PubMed ID: 20890081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.